Table 1.
Characteristics of study population overall and according to whether or not DRMs were detected.
| Characteristic | Overall | DRMs detected | No DRMs detected | P value* |
|---|---|---|---|---|
| Number of subjects | 69 | 6 (8.7%) | 63 | |
|
| ||||
| Country of origin: | ||||
| Argentina | 5 (7.2%) | 0 (0.0%) | 5 | 0.74 |
| Brazil | 55 (79.7%) | 6 (10.9%) | 49 | |
| Mexico | 9 (13.0%) | 0 (0.0%) | 9 | |
|
| ||||
| Age at enrollment (years): | ||||
| Mean (SD) | 7.3 (6.0) | 5.2 (0.8) | 7.5 (6.2) | 0.64 |
| Median | 6.0 | 5.0 | 6.0 | |
|
| ||||
| Gender: | ||||
| Female | 40 (58.0%) | 3 (7.5%) | 37 | 0.69 |
| Male | 29 (42.0%) | 3 (10.3%) | 26 | |
|
| ||||
| Subject's risk for HIV infection: | ||||
| Blood product transfusion | 1 (1.5%) | 0 (0.0%) | 1 | 1.00 |
| Consensual sexual contact | 8 (11.6%) | 0 (0.0%) | 8 | |
| Perinatal exposure | 56 (81.2%) | 6 (10.7%) | 50 | |
| Unknown | 4 (5.8%) | 0 (0.0%) | 4 | |
|
| ||||
| Among perinatally infected, did mother take ARVs during pregnancy or at labor and delivery? | ||||
| Yes | 7 (12.5%) | 0 (0.0%) | 7 | 0.55 |
| No | 44 (78.6%) | 5 (11.4%) | 39 | |
| Unknown | 5 (8.9%) | 1 (1.8%) | 4 | |
|
| ||||
| CD4 percent at or nearest to the time when the resistance testing specimen was collected: | ||||
| Mean (SD) | 24.2 (10.9) | 25.2 (8.6) | 24.1 (11.2) | 0.42 |
| Median | 24.0 | 28.0 | 23.0 | |
| <15% | 11 (17.5%) | 1 (9.1%) | 10 | 0.64 |
| 15–24.9% | 23 (36.5%) | 1 (4.3%) | 22 | |
| ≥25% | 29 (46.0%) | 4 (13.8%) | 25 | |
| Missing | 6 | 0 | 6 | |
|
| ||||
| CD4 absolute count (cells/mm3) at or nearest to the time when the resistance testing specimen was collected: | ||||
| Mean (SD) | 779 (615) | 769 (354) | 780 (637) | 0.65 |
| Median | 668 | 678 | 668 | |
| <200 cells/mm3 | 9 (13.2%) | 0 (0.0%) | 9 | 0.84 |
| 200–500 | 16 (23.5%) | 1 (6.3%) | 15 | |
| >500 | 43 (63.2%) | 5 (11.6%) | 38 | |
| Missing | 1 | 0 | 1 | |
|
| ||||
| CDC clinical classification: | ||||
| Category N | 18 (26.5%) | 4 (22.2%) | 14 | 0.09 |
| Category A | 9 (13.2%) | 1 (11.1%) | 8 | |
| Category B | 4 (5.9%) | 0 (0.0%) | 4 | |
| Category C | 37 (54.4%) | 1 (2.7%) | 36 | |
| Missing | 1 | 0 | 1 | |
|
| ||||
| HIV-1 viral load (copies/mL) at or nearest to the time when the resistance testing specimen was collected: | ||||
| Mean | 214,448 | 34,062 | 232,191 | 0.25 |
| SD | 522,665 | 31,248 | 544,831 | |
| Median | 40,100 | 25,521 | 44,000 | |
| Vital status of study subject: | ||||
| Dead | 1 (1.4%) | 0 (0.0%) | 1 | 1.00 |
| Alive | 68 (98.6%) | 6 (8.8%) | 62 | |
*The significance of associations of categorical characteristics with DRMs was determined based on Fisher's Exact test, while the association with continuous scaled characteristics was based on the Student's t-test (log10-transformed viral load) or nonparametric testing (Wilcoxon test).